• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Artesunate-amodiaquine therapy linked to lower Ebola mortality

byMatthew Lin, MDandShaidah Deghan, MSc. MD
January 8, 2016
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

 

1. Artesunate-amodiaquine (AA) treated Ebola patients had a significantly lower risk of death than artemether-lumefantrine (AL) treated patients.

2. The effect reduced mortality associated with AA treatment in comparison to AL was attenuated when the study population was stratified a positive malaria test.

Evidence Rating Level: 2 (Good)  

Study Rundown: Since the outbreak of Ebola virus disease (EVD) in West Africa back in March 2014, the FDA has approved several artemisinin-based antimalarial drugs that have demonstrated in vitro anti-EVD activity. In this retrospective cohort study, researchers analyzed patient data from an Ebola treatment center in Foya, Liberia. Per protocol, patients diagnosed with EVD at the center were treated with prophylactic antibiotics and a 3-day course of AL, an antimalarial therapy. However, in August 2014, the center experienced a temporary shortage of AL, and patients were alternatively prescribed a 3-day course of AA – a therapy that is sometimes recommended as second-line to AL due to amodiaquine’s potential hepatotoxicity when used as long-term prophylaxis. In this retrospective cohort study, researchers analyzed mortality rates between patients prescribed AA and AL, finding a significantly lower risk of death in the AA group compared to the AL group. However, this effect was not significant when patients were stratified by positive malaria status. The data in this study are limited by possible temporal-related differences between AA vs. AL groups, as patients in the two groups were admitted at different times. Other limitations acknowledged by the authors included lack of data on patient completion of full drug regimen. Overall, this study suggests that AA may provide more protection against mortality than AL.

Click to read the study, published today in NEJM

Relevant Reading: A systematic screen of FDA-approved drugs for inhibitors of biological threat agents

RELATED REPORTS

2 Minute Medicine Rewind October 16, 2017

Recombinant vesicular stomatitis virus vaccine elicits anti-Ebola seroconversion

2 Minute Medicine Rewind October 17, 2016

In-Depth [retrospective cohort]: In this retrospective cohort study, a total of 382 patients (one excluded for lack of outcome data) were categorized into four groups: EVD patients prescribed AL, AA, no antimalarials or EVD patients with no prescription information. Mortality was higher in the AL group versus the AA group (64.6% vs. 51%). In an analysis adjusted for potential confounding factors, the AA group had a 31% lower risk of death compared to the AL group (RR=0.69, 95%[CI]=0.54-0.89). After stratifying mortality between AA and AL groups based on malaria diagnosis, the authors found no difference in adjusted mortality risk in patients positive for malaria (RR=1.0, 95%[CI]=0.54-1.85, p=0.98). However, there was a significantly lower adjusted mortality risk between the AA and AL group in patients that tested negative for malaria (RR=0.64, 95%[CI]=0.63-1.01, p=0.06). However, in patients with a positive malaria status, treatment with any antimalarial agent reduced the risk of mortality compared to no antimalarial treatment at all. 

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Artesunate-amodiaquineebola
Previous Post

Reducing sugars in sweetened drinks may prevent up to 1 million adults from becoming obese in the UK

Next Post

Youth ice hockey concussion rate comparable to other sports

RelatedReports

Concomitant HPV vaccine administration equivalent to staggered schedule
Weekly Rewinds

2 Minute Medicine Rewind October 16, 2017

October 25, 2017
Concomitant HPV vaccine administration equivalent to staggered schedule
Infectious Disease

Recombinant vesicular stomatitis virus vaccine elicits anti-Ebola seroconversion

January 26, 2017
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Weekly Rewinds

2 Minute Medicine Rewind October 17, 2016

October 24, 2016
2 Minute Medicine Rewind November 23 – November 30, 2014
Infectious Disease

Modified vaccinia Ankara booster increases immunogenic response in Ebola Virus disease

May 8, 2016
Next Post
Youth ice hockey concussion rate comparable to other sports

Youth ice hockey concussion rate comparable to other sports

Oral fluconazole in pregnancy associated with miscarriage

Oral fluconazole in pregnancy associated with miscarriage

Atrial fibrillation-specific management increases days alive and out of hospital

2 Minute Medicine Rewind January 11, 2016

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.